6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Bleeding O
, O
including O
life-threatening O
and O
fatal O
bleeding O
, O
is O
the O
most O
commonly O
reported O
adverse O
reaction O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eli O
Lilly O
and O
Company O
at O
1-800-545-5979 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
The O
following O
serious O
adverse O
reactions O
are O
also O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Bleeding B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Safety O
in O
patients O
with O
ACS B-Not_AE_Candidate
undergoing O
PCI O
was O
evaluated O
in O
a O
clopidogrel-controlled O
study O
, O
TRITON-TIMI O
38 O
, O
in O
which O
6741 O
patients O
were O
treated O
with O
Effient O
( O
60-mg O
loading O
dose O
and O
10-mg O
once O
daily O
) O
for O
a O
median O
of O
14.5 O
months O
( O
5802 O
patients O
were O
treated O
for O
over O
6 O
months O
; O
4136 O
patients O
were O
treated O
for O
more O
than O
1 O
year O
) O
. O

The O
population O
treated O
with O
Effient O
was O
27 O
to O
96 O
years O
of O
age O
, O
25 O
% O
female O
, O
and O
92 O
% O
Caucasian O
. O

All O
patients O
in O
the O
TRITON-TIMI O
38 O
study O
were O
to O
receive O
aspirin O
. O

The O
dose O
of O
clopidogrel O
in O
this O
study O
was O
a O
300-mg O
loading O
dose O
and O
75-mg O
once O
daily O
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
can O
not O
be O
directly O
compared O
with O
the O
rates O
observed O
in O
other O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Drug O
Discontinuation O
The O
rate O
of O
study O
drug O
discontinuation O
because O
of O
adverse O
reactions O
was O
7.2 O
% O
for O
Effient O
and O
6.3 O
% O
for O
clopidogrel O
. O

Bleeding B-OSE_Labeled_AE
was O
the O
most O
common O
adverse O
reaction O
leading O
to O
study O
drug O
discontinuation O
for O
both O
drugs O
( O
2.5 O
% O
for O
Effient O
and O
1.4 O
% O
for O
clopidogrel O
) O
. O

Bleeding O
Bleeding B-NonOSE_AE
Unrelated O
to O
CABG O
Surgery O
- O
In O
TRITON-TIMI O
38 O
, O
overall O
rates O
of O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
adverse O
reactions O
unrelated O
to O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
were O
significantly O
higher O
on O
Effient O
than O
on O
clopidogrel O
, O
as O
shown O
in O
Table O
1 O
. O

Table O
1 O
: O
Non-CABG-Related O
Bleedinga O
( O
TRITON-TIMI O
38 O
) O
a O
Patients O
may O
be O
counted O
in O
more O
than O
one O
row O
. O

b O
See O
5.1 O
for O
definition O
. O

Effient O
( O
% O
) O
( O
N=6741 O
) O
Clopidogrel O
( O
% O
) O
( O
N=6716 O
) O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
4.5 O
3.4 O
TIMI O
Major O
bleeding B-OSE_Labeled_AE
b O
2.2 O
1.7 O
Life-threatening O
1.3 O
0.8 O
Fatal B-NonOSE_AE
0.3 O
0.1 O
Symptomatic O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ICH I-OSE_Labeled_AE
) O
0.3 O
0.3 O
Requiring O
inotropes O
0.3 O
0.1 O
Requiring O
surgical O
intervention O
0.3 O
0.3 O
Requiring O
transfusion O
( O
> O
=4 O
units O
) O
0.7 O
0.5 O
TIMI O
Minor O
bleeding B-OSE_Labeled_AE
b O
2.4 O
1.9 O
Figure O
1 O
demonstrates O
non-CABG O
related O
TIMI O
Major O
or O
Minor O
bleeding B-NonOSE_AE
. O

The O
bleeding B-NonOSE_AE
rate O
is O
highest O
initially O
, O
as O
shown O
in O
Figure O
1 O
( O
inset O
: O
Days O
0 O
to O
7 O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Bleeding B-NonOSE_AE
by O
Weight O
and O
Age O
- O
In O
TRITON-TIMI O
38 O
, O
non-CABG-related O
TIMI O
Major O
or O
Minor O
bleeding B-NonOSE_AE
rates O
in O
patients O
with O
the O
risk O
factors O
of O
age O
> O
=75 O
years O
and O
weight O
< O
60 O
kg O
are O
shown O
in O
Table O
2 O
. O

Table O
2 O
: O
Bleeding B-OSE_Labeled_AE
Rates O
for O
Non-CABG-Related O
Bleeding O
by O
Weight O
and O
Age O
( O
TRITON-TIMI O
38 O
) O
a O
10-mg O
Effient O
maintenance O
dose O
b O
75-mg O
clopidogrel O
maintenance O
dose O
Major/Minor O
Fatal O
Effienta O
( O
% O
) O
Clopidogrelb O
( O
% O
) O
Effienta O
( O
% O
) O
Clopidogrelb O
( O
% O
) O
Weight O
< O
60 O
kg O
( O
N=308 O
Effient O
, O
N=356 O
clopidogrel O
) O
10.1 O
6.5 O
0.0 O
0.3 O
Weight O
> O
=60 O
kg O
( O
N=6373 O
Effient O
, O
N=6299 O
clopidogrel O
) O
4.2 O
3.3 O
0.3 O
0.1 O
Age O
< O
75 O
years O
( O
N=5850 O
Effient O
, O
N=5822 O
clopidogrel O
) O
3.8 O
2.9 O
0.2 O
0.1 O
Age O
> O
=75 O
years O
( O
N=891 O
Effient O
, O
N=894 O
clopidogrel O
) O
9.0 O
6.9 O
1.0 O
0.1 O
Bleeding B-NonOSE_AE
Related O
to O
CABG O
- O
In O
TRITON-TIMI O
38 O
, O
437 O
patients O
who O
received O
a O
thienopyridine O
underwent O
CABG O
during O
the O
course O
of O
the O
study O
. O

The O
rate O
of O
CABG-related O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
was O
14.1 O
% O
for O
the O
Effient O
group O
and O
4.5 O
% O
in O
the O
clopidogrel O
group O
( O
see O
Table O
3 O
) O
. O

The O
higher O
risk O
for O
bleeding B-OSE_Labeled_AE
adverse O
reactions O
in O
patients O
treated O
with O
Effient O
persisted O
up O
to O
7 O
days O
from O
the O
most O
recent O
dose O
of O
study O
drug O
. O

Table O
3 O
: O
CABG-Related O
Bleedinga O
( O
TRITON-TIMI O
38 O
) O
a O
Patients O
may O
be O
counted O
in O
more O
than O
one O
row O
. O

Effient O
( O
% O
) O
( O
N=213 O
) O
Clopidogrel O
( O
% O
) O
( O
N=224 O
) O
TIMI O
Major O
or O
Minor O
bleeding B-OSE_Labeled_AE
14.1 O
4.5 O
TIMI O
Major O
bleeding B-OSE_Labeled_AE
11.3 O
3.6 O
Fatal B-NonOSE_AE
0.9 O
0 O
Reoperation O
3.8 O
0.5 O
Transfusion O
of O
> O
=5 O
units O
6.6 O
2.2 O
Intracranial B-NonOSE_AE
hemorrhage I-NonOSE_AE
0 O
0 O
TIMI O
Minor O
bleeding B-OSE_Labeled_AE
2.8 O
0.9 O
Bleeding B-NonOSE_AE
Reported O
as O
Adverse O
Reactions O
- O
Hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
reported O
as O
adverse O
reactions O
in O
TRITON-TIMI O
38 O
were O
, O
for O
Effient O
and O
clopidogrel O
, O
respectively O
: O
epistaxis B-OSE_Labeled_AE
( O
6.2 O
% O
, O
3.3 O
% O
) O
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
1.5 O
% O
, O
1.0 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
( O
0.6 O
% O
, O
0.5 O
% O
) O
, O
subcutaneous B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
( O
0.5 O
% O
, O
0.2 O
% O
) O
, O
post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
procedural I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.5 O
% O
, O
0.2 O
% O
) O
, O
retroperitoneal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.3 O
% O
, O
0.2 O
% O
) O
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
/ O
hemorrhage B-OSE_Labeled_AE
/tamponade O
( O
0.3 O
% O
, O
0.2 O
% O
) O
, O
and O
retinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
0.0 O
% O
, O
0.1 O
% O
) O
. O

Malignancies O
During O
TRITON-TIMI O
38 O
, O
newly-diagnosed O
malignancies B-OSE_Labeled_AE
were O
reported O
in O
1.6 O
% O
and O
1.2 O
% O
of O
patients O
treated O
with O
prasugrel O
and O
clopidogrel O
, O
respectively O
. O

The O
sites O
contributing O
to O
the O
differences O
were O
primarily O
colon I-OSE_Labeled_AE
and O
lung O
. O

In O
another O
Phase O
3 O
clinical O
study O
of O
ACS B-Not_AE_Candidate
patients O
not O
undergoing O
PCI O
, O
in O
which O
data O
for O
malignancies B-NonOSE_AE
were O
prospectively O
collected O
, O
newly-diagnosed O
malignancies B-NonOSE_AE
were O
reported O
in O
1.8 O
% O
and O
1.7 O
% O
of O
patients O
treated O
with O
prasugrel O
and O
clopidogrel O
, O
respectively O
. O

The O
site O
of O
malignancies B-NonOSE_AE
was O
balanced O
between O
treatment O
groups O
except O
for O
colorectal B-NonOSE_AE
malignancies I-NonOSE_AE
. O

The O
rates O
of O
colorectal B-OSE_Labeled_AE
malignancies I-OSE_Labeled_AE
were O
0.3 O
% O
prasugrel O
, O
0.1 O
% O
clopidogrel O
and O
most O
were O
detected O
during O
investigation O
of O
GI B-Not_AE_Candidate
bleed I-Not_AE_Candidate
or O
anemia B-Not_AE_Candidate
. O

It O
is O
unclear O
if O
these O
observations O
are O
causally-related O
, O
are O
the O
result O
of O
increased O
detection O
because O
of O
bleeding B-NonOSE_AE
, O
or O
are O
random O
occurrences O
. O

Other O
Adverse O
Events O
In O
TRITON-TIMI O
38 O
, O
common O
and O
other O
important O
non B-NonOSE_AE
- I-NonOSE_AE
hemorrhagic I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
were O
, O
for O
Effient O
and O
clopidogrel O
, O
respectively O
: O
severe O
thrombocytopenia B-OSE_Labeled_AE
( O
0.06 O
% O
, O
0.04 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
2.2 O
% O
, O
2.0 O
% O
) O
, O
abnormal B-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
function I-OSE_Labeled_AE
( O
0.22 O
% O
, O
0.27 O
% O
) O
, O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
0.36 O
% O
, O
0.36 O
% O
) O
, O
and O
angioedema B-OSE_Labeled_AE
( O
0.06 O
% O
, O
0.04 O
% O
) O
. O

Table O
4 O
summarizes O
the O
adverse O
events O
reported O
by O
at O
least O
2.5 O
% O
of O
patients O
. O

Table O
4 O
: O
Non-Hemorrhagic O
Treatment O
Emergent O
Adverse O
Events O
Reported O
by O
at O
Least O
2.5 O
% O
of O
Patients O
in O
Either O
Group O
Effient O
( O
% O
) O
( O
N=6741 O
) O
Clopidogrel O
( O
% O
) O
( O
N=6716 O
) O
Hypertension B-OSE_Labeled_AE
7.5 O
7.1 O
Hypercholesterolemia B-OSE_Labeled_AE
/ O
Hyperlipidemia B-OSE_Labeled_AE
7.0 O
7.4 O
Headache B-OSE_Labeled_AE
5.5 O
5.3 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
5.0 O
4.5 O
Dyspnea B-OSE_Labeled_AE
4.9 O
4.5 O
Nausea B-OSE_Labeled_AE
4.6 O
4.3 O
Dizziness B-OSE_Labeled_AE
4.1 O
4.6 O
Cough B-OSE_Labeled_AE
3.9 O
4.1 O
Hypotension B-OSE_Labeled_AE
3.9 O
3.8 O
Fatigue B-OSE_Labeled_AE
3.7 O
4.8 O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
chest I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3.1 O
3.5 O
Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
2.9 O
3.1 O
Bradycardia B-OSE_Labeled_AE
2.9 O
2.4 O
Leukopenia B-OSE_Labeled_AE
( O
< B-OSE_Labeled_AE
4 I-OSE_Labeled_AE
x I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
WBC I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
) O
2.8 O
3.5 O
Rash B-OSE_Labeled_AE
2.8 O
2.4 O
Pyrexia B-OSE_Labeled_AE
2.7 O
2.2 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
2.7 O
3.0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
2.6 O
2.6 O
Diarrhea B-OSE_Labeled_AE
2.3 O
2.6 O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
Effient O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
- O
Thrombocytopenia B-OSE_Labeled_AE
, O
Thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
TTP O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
- O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
[ O
see O
Contraindications O
( O
4.3 O
) O
] O

